EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical relevance and therapeutic predictive ability of hypoxia biomarkers in head and neck cancer tumour models

Tet Woo Lee, Dean C Singleton, Julia K Harms, Man Lu, Sarah P McManaway, Amy Lai, Moana Tercel, Frederik B Pruijn, Andrew M J Macann, Francis W Hunter, William R Wilson, Stephen M F Jamieson iD

Molecular Oncology · 2024-08 · 18 (8) · 1885-1903

DOI: 10.1002/1878-0261.13620 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Oncology, 2024-03. Verfasst von Tet Woo Lee und 11 weiteren Autor:innen. Beteiligte Einrichtung: Auckland Cancer Society Research Centre, University of Auckland, New Zealand. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Head and Neck Neoplasms, Squamous Cell Carcinoma of Head and Neck, Xenograft Model Antitumor Assays. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Research Council of New Zealand, Cancer Society Auckland and Northland Division.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tumour hypoxia promotes poor patient outcomes, with particularly strong evidence for head and neck squamous cell carcinoma (HNSCC). To effectively target hypoxia, therapies require selection biomarkers and preclinical models that can accurately model tumour hypoxia. We established 20 patient‐derived xenograft (PDX) and cell line‐derived xenograft (CDX) models of HNSCC that we characterised for their fidelity to represent clinical HNSCC in gene expression, hypoxia status and proliferation and that were evaluated for their sensitivity to hypoxia‐activated prodrugs (HAPs). PDX models showed greater fidelity in gene expression to clinical HNSCC than cell lines, as did CDX models relative to their paired cell lines. PDX models were significantly more hypoxic than CDX models, as assessed by hypoxia gene signatures and pimonidazole immunohistochemistry, and showed similar hypoxia gene expression to clinical HNSCC tumours. Hypoxia or proliferation status alone could not determine HAP sensitivity across our 20 HNSCC and two non‐HNSCC tumour models by either tumour growth inhibition or killing of hypoxia cells in an ex vivo clonogenic assay. In summary, our tumour models provide clinically relevant HNSCC models that are suitable for evaluating hypoxia‐targeting therapies; however, additional biomarkers to hypoxia are required to accurately predict drug sensitivity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biomarkers, TumorHead and Neck NeoplasmsSquamous Cell Carcinoma of Head and NeckXenograft Model Antitumor AssaysAnimalsHumansMiceCell HypoxiaCell Line, TumorCell ProliferationClinical RelevanceNitroimidazolesProdrugsTumor Hypoxia

Stichwörter der Autor:innen

evofosfamidehead and neck squamous cell carcinomahypoxiahypoxia‐activated prodrugspimonidazoletumour xenografts

Substanzen

Biomarkers, TumorNitroimidazolespimonidazoleProdrugs

Autor:innen und Institutionen

  • Auckland Cancer Society Research Centre, University of Auckland, New Zealand.
  • Maurice Wilkins Centre for Molecular Biodiscovery, University of Auckland, New Zealand.
  • Department of Molecular Medicine and Pathology, University of Auckland, New Zealand.
  • Department of Pharmacology and Clinical Pharmacology, University of Auckland, New Zealand.
  • Department of Radiation Oncology, Auckland City Hospital, New Zealand.
  • Oncology Therapeutic Area, Janssen Research and Development, Spring House, PA, USA.

ORCID-Profile: Stephen M F Jamieson

Förderung

  • Health Research Council of New Zealand
  • Cancer Society Auckland and Northland Division

Zitieren

APA

Lee, T. W., Singleton, D. C., Harms, J. K., Lu, M., McManaway, S. P., Lai, A., Tercel, M., Pruijn, F. B., Macann, A. M. J., Hunter, F. W., Wilson, W. R., & Jamieson, S. M. F. (2024). Clinical relevance and therapeutic predictive ability of hypoxia biomarkers in head and neck cancer tumour models. Molecular Oncology, 18(8), 1885-1903. https://doi.org/10.1002/1878-0261.13620

Vancouver

Lee TW, Singleton DC, Harms JK, Lu M, McManaway SP, Lai A, et al. Clinical relevance and therapeutic predictive ability of hypoxia biomarkers in head and neck cancer tumour models. Molecular Oncology. 2024;18(8):1885-1903. doi:10.1002/1878-0261.13620

BibTeX
@article{Lee2024,
  author = {Lee, Tet Woo and Singleton, Dean C and Harms, Julia K and Lu, Man and McManaway, Sarah P and Lai, Amy and Tercel, Moana and Pruijn, Frederik B and Macann, Andrew M J and Hunter, Francis W and Wilson, William R and Jamieson, Stephen M F},
  title = {Clinical relevance and therapeutic predictive ability of hypoxia biomarkers in head and neck cancer tumour models},
  journal = {Molecular Oncology},
  year = {2024},
  volume = {18},
  number = {8},
  pages = {1885--1903},
  doi = {10.1002/1878-0261.13620}
}
Kostenlos starten →